|
As mentioned during the January business meeting, commission staff are working on a HCE FAQ. If you have suggestions for the staff to consider for this HCE FAQ, please email WSPQAC@doh.wa.gov no later than Tuesday, January 31, 2023.
We continue to receive reports of fraudulent prescriptions. Please remember, you may report suspected fraudulent prescriptions to Rx Fraud Alerts form (web-based) as well as view past reports.
This information is from the Substance Abuse and Mental Health Services Administration (SAMHSA):
Section 1262 of the Consolidated Appropriations Act, 2023 (also known as Omnibus bill), removes the federal requirement for practitioners to submit a Notice of Intent (have a waiver) to prescribe buprenorphine for the treatment of opioid use disorder (OUD). With this provision, and effective immediately, SAMHSA will no longer be accepting NOIs (waiver applications). All practitioners who have a current DEA registration that includes Schedule III authority may now prescribe buprenorphine for Opioid Use Disorder in their practice if permitted by applicable state law.
SAMHSA and DEA are actively working on implementation of a separate provision of the Omnibus related to training requirements for DEA registration that becomes effective in June 2023. For further updates and guidance, please continue to check this webpage and the Medication-Assisted Treatment (MAT) section of the SAMHSA website, www.samhsa.gov.
PQAC's weekly 2023 legislative call will be at noon Friday, January 20, 2023. Please follow the link to the agenda and bill report. Commission staff will present legislation impacting the practice of pharmacy in Washington State.
No registration is required. Simply join here or log into Zoom with webinar ID 823 1715 3848. (The meeting links/#s to all legislative calls/meetings are valid through 2023.)
|
